Developer docs
API playgroundTry for free, no card

Search company profiles

AxoGen

Full company profile

uuid0002ggx

Namestring
AxoGen
Legal namestring
Axogen Corporation
Websiteurl
axogeninc.com
Company typeenum
Public
Founded yearint
2002
Descriptiontext

AxoGen (NASDAQ: AXGN) is a publicly traded biotechnology and medical device company founded in 2002 and headquartered in Alachua, Florida (with corporate leadership in Tampa, FL). The company develops and commercializes surgical technologies for peripheral nerve repair, addressing nerve discontinuities, compression injuries, and neuroma prevention across three primary commercial markets: Extremities, Breast Reconstruction (including the Resensation technique), and Oral Maxillofacial/Head & Neck procedures. The company operates an FDA-regulated 24/7 tissue processing facility in Vandalia, Ohio, and a global distribution facility in Burleson, Texas, with wholly-owned subsidiaries in Germany for European market reach.

The product portfolio centers on two technology platforms: (1) Avance, an acellular nerve allograft that received FDA Biologics License Application approval on December 3, 2025, becoming the first and only FDA-approved biologic therapeutic for peripheral nerve discontinuities with 12 years of market exclusivity; and (2) the Axoguard family of porcine small intestine submucosa (SIS)-based devices, including the Nerve Connector (for gaps up to 5mm), Nerve Protector, HA+ Nerve Protector (with resorbable hyaluronate-alginate coating), and Nerve Cap (for neuroma prevention). The portfolio is rounded out by Avive+ Soft Tissue Matrix, a multi-layer amnion barrier. The company holds ISO 13485 certification, AATB accreditation, and multiple state tissue bank licenses.

AxoGen generates revenue through direct field sales to hospitals, ambulatory surgical centers, and surgeons across the United States. Products are sold one-time per procedure via surgeon-directed purchasing, with pricing determined by hospital procurement and insurance coverage rather than public disclosure. The company partners with Musculoskeletal Clinical Regulatory Advisers (MCRA) for coding and reimbursement support, and reports approximately 86% domestic covered lives insured following Cigna and Elevance Health positive coverage decisions. Full-year 2025 revenue was $225.2 million (20.2% YoY growth), with Q1 2026 reaching $61.5 million (26.6% YoY growth) and 2026 guidance of at least $270 million. The company became debt-free in January 2026 following a $133.3 million public offering.

Short descriptiontext

AxoGen (NASDAQ: AXGN) develops and commercializes FDA-regulated biologic and medical device products for surgical peripheral nerve repair, serving hospitals, surgeons, and patients across Extremities, Breast Reconstruction, and Oral Maxillofacial/Head & Neck markets in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAlachua, United States
HQ citystring
Alachua
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral nerve repair, nerve allograft products, surgical nerve connectors, biologic nerve grafts, soft tissue matrix
Industry2 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Nerve Repair Products
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device and Biologic Product Sales
TypeOne Time License
Description

Revenue generated from the sale of peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Products sold directly to hospitals and surgical facilities for use in nerve repair procedures. Revenue is one-time per procedure with recurring account relationships.

ir.axogeninc.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Avance
Description

FDA-approved acellular nerve allograft for peripheral nerve discontinuities

axogeninc.com
+3 more records
Core offering1 text field

AxoGen develops, manufactures, and markets a portfolio of medical devices and biologic products for the surgical repair of peripheral nerve injuries. Its offerings include the FDA-approved Avance acellular nerve allograft and the Axoguard family of porcine small intestine submucosa (SIS)-based nerve connectors, protectors, and caps, plus the Avive+ Soft Tissue Matrix. Products are sold to hospitals, ambulatory surgical centers, and surgeons for use in extremity, breast reconstruction, and oral maxillofacial/head & neck nerve repair procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 23.5% year-over-year revenue growth in Q3 2025
+4 more records
Product overview1 text field

AxoGen offers a comprehensive suite of surgical products for peripheral nerve repair. The portfolio includes Avance (FDA-approved biologic nerve allograft), the Axoguard family of SIS-based devices (Nerve Connector, Nerve Protector, HA+ Nerve Protector, Nerve Cap), and Avive+ Soft Tissue Matrix. These products address the full spectrum of nerve repair scenarios: Avance provides an acellular nerve scaffold for bridging gaps, the Nerve Connector enables tension-free coaptation for small gaps, the Nerve Protectors wrap and shield injured nerves from soft tissue attachments, the Nerve Cap prevents neuroma formation, and Avive+ provides soft tissue separation. The company transitioned from a medical device platform to a regulated biologics business following FDA approval of Avance in December 2025.

Product and service6 records
1Avance Acellular Nerve Allograft
CategoryBiologic nerve graft
Description

FDA-approved acellular nerve allograft serving as a biologic scaffold for nerve regrowth across peripheral nerve discontinuities in patients aged one month and older. Indicated for surgical nerve repair procedures performed by peripheral nerve, trauma, breast reconstruction, and oral maxillofacial surgeons.

2Axoguard Nerve Connector
CategoryNerve coaptation device
Description

Porcine small intestine submucosa (SIS) matrix designed for Connector Assisted Repair of transected nerves with gaps up to 5mm, alleviating tension at the repair site and aiding nerve end alignment for peripheral nerve surgeons.

3Axoguard Nerve Protector
CategoryNerve protection device
Description

Porcine small intestine submucosa (SIS) implant with a pre-curled design for circumferential wrapping of injured or compressed nerves, minimizing soft tissue attachments during healing for use by peripheral nerve and reconstructive surgeons.

4Axoguard HA+ Nerve Protector
CategoryNerve protection device
Description

SIS-based nerve protector with a short-term resorbable hyaluronate-alginate gel coating designed to enhance nerve gliding and minimize soft tissue attachments during the critical healing phase for peripheral nerve and reconstructive surgeons.

5Axoguard Nerve Cap
CategoryNeuroma prevention device
Description

Porcine small intestine submucosa (SIS) matrix with proprietary bifurcation design intended to reduce the development of symptomatic or painful neuromas by minimizing pathological axon interaction, for use in neuroma prevention procedures.

6Avive+ Soft Tissue Matrix
CategorySoft tissue barrier
Description

Multi-layer amnion intended for use as a soft tissue barrier in acutely inflamed or irritated environments, resorbing over 16 weeks to provide barrier function through the critical healing phase for surgical applications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

AxoGen provides experienced coding assistance and Coverage Access Services through MCRA as consulting partner. MCRA staff provides guidance on CPT and ICD-10 codes, claim submission, benefits verification, pre-authorization assistance, and payer-specific pre-determination requests.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Stryker is a diversified medical device incumbent with surgical, orthopedic, and neurotechnology portfolios that overlap with Axogen's extremity and reconstructive surgical call points. As a large incumbent, Stryker has the scale and R&D resources to enter the nerve repair space.

TypeBroad incumbent
Description

Medtronic has a strong neurosurgery and ENT portfolio and active peripheral nerve stimulation offerings (e.g., Intellis, Vanta). It serves overlapping surgical specialists and could expand into nerve repair biologics from a position of strength.

TypeEmerging player
Description

Organogenesis is a regenerative medicine company with leading skin substitute products (Apligraf, Dermagraft) targeting wound care and surgical applications adjacent to Axogen's nerve repair and Avive+ matrix portfolio.

4Cook Medical
TypeBroad incumbent
Description

Cook Medical sells a broad range of surgical implants and biologic devices (including the Biodesign SIS-based surgical products) that overlap with Axogen's porcine SIS-based Axoguard line in soft tissue and reconstructive surgery.

TypeBroad incumbent
Description

Coloplast is a broad wound and skin care incumbent with Biatain and other advanced wound care products. While not a nerve repair specialist, it competes for surgical wound healing budgets and shares reimbursement-driven hospital channels with Axogen.

TypeEmerging player
Description

Vericel is a regenerative medicine specialist (MACI, Epicel) targeting surgical and sports medicine indications. While focused on cartilage and burns, it uses a similar hospital-based specialty sales model and biologic reimbursement strategy to Axogen.

TypeDirect peer
Description

MiMedx markets EpiFix and AmnioFix amniotic membrane allografts that directly overlap with Axogen's Avive+ Soft Tissue Matrix in surgical and wound applications. Both compete in regenerative soft tissue and use similar direct-to-surgeon field sales models.

TypeDirect peer
Description

Integra is the most direct competitor in peripheral nerve repair, selling NeuraGen nerve guides and NeuraWrap/NeuraWrap+ protectors for nerve coaptation. Both companies target the same hand, plastic, and trauma surgeons with surgical nerve repair solutions.

TypeBroad incumbent
Description

ConvaTec is a global wound and skin care company with advanced wound biologics (e.g., InnovaMatrix) that overlap with Axogen's Avive+ soft tissue matrix and compete for the same surgical reimbursement codes.

TypeBroad incumbent
Description

Smith+Nephew is a diversified incumbent with strong surgical and regenerative medicine franchises (including acquired Osiris cartilage and skin products) that overlap with Axogen's regenerative nerve and soft tissue repair products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AxoGen

Surgical Nerve Repair Productsaxogeninc.com

AxoGen (NASDAQ: AXGN) develops and commercializes FDA-regulated biologic and medical device products for surgical peripheral nerve repair, serving hospitals, surgeons, and patients across Extremities, Breast Reconstruction, and Oral Maxillofacial/Head & Neck markets in the United States.

What AxoGen does

AxoGen (NASDAQ: AXGN) is a publicly traded biotechnology and medical device company founded in 2002 and headquartered in Alachua, Florida (with corporate leadership in Tampa, FL). The company develops and commercializes surgical technologies for peripheral nerve repair, addressing nerve discontinuities, compression injuries, and neuroma prevention across three primary commercial markets: Extremities, Breast Reconstruction (including the Resensation technique), and Oral Maxillofacial/Head & Neck procedures. The company operates an FDA-regulated 24/7 tissue processing facility in Vandalia, Ohio, and a global distribution facility in Burleson, Texas, with wholly-owned subsidiaries in Germany for European market reach.

The product portfolio centers on two technology platforms: (1) Avance, an acellular nerve allograft that received FDA Biologics License Application approval on December 3, 2025, becoming the first and only FDA-approved biologic therapeutic for peripheral nerve discontinuities with 12 years of market exclusivity; and (2) the Axoguard family of porcine small intestine submucosa (SIS)-based devices, including the Nerve Connector (for gaps up to 5mm), Nerve Protector, HA+ Nerve Protector (with resorbable hyaluronate-alginate coating), and Nerve Cap (for neuroma prevention). The portfolio is rounded out by Avive+ Soft Tissue Matrix, a multi-layer amnion barrier. The company holds ISO 13485 certification, AATB accreditation, and multiple state tissue bank licenses.

AxoGen generates revenue through direct field sales to hospitals, ambulatory surgical centers, and surgeons across the United States. Products are sold one-time per procedure via surgeon-directed purchasing, with pricing determined by hospital procurement and insurance coverage rather than public disclosure. The company partners with Musculoskeletal Clinical Regulatory Advisers (MCRA) for coding and reimbursement support, and reports approximately 86% domestic covered lives insured following Cigna and Elevance Health positive coverage decisions. Full-year 2025 revenue was $225.2 million (20.2% YoY growth), with Q1 2026 reaching $61.5 million (26.6% YoY growth) and 2026 guidance of at least $270 million. The company became debt-free in January 2026 following a $133.3 million public offering.

AxoGen firmographics

Firmographics
Name
AxoGen
Legal name
Axogen Corporation
Website
https://axogeninc.com
Company type
Public
Founded year
2002
Operating status
Operating
Headcount range
501–1,000 employees
Short description
AxoGen (NASDAQ: AXGN) develops and commercializes FDA-regulated biologic and medical device products for surgical peripheral nerve repair, serving hospitals, surgeons, and patients across Extremities, Breast Reconstruction, and Oral Maxillofacial/Head & Neck markets in the United States.
Ownership category
akta.pro rank

AxoGen industry classification

Industry
Product category
Surgical Nerve Repair Products
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Peripheral nerve repair
  • Nerve allograft products
  • Surgical nerve connectors
  • Biologic nerve grafts
  • Soft tissue matrix

Where AxoGen is headquartered

Location

Headquarters

HQ city
Alachua
HQ country
United States
HQ region
North America

Offices4 records

Markets served

AxoGen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Medical Device and Biologic Product Sales: Revenue generated from the sale of peripheral nerve repair products including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Products sold directly to hospitals and surgical facilities for use in nerve repair procedures. Revenue is one-time per procedure with recurring account relationships.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

AxoGen product offering

Product offering

Core offering

AxoGen develops, manufactures, and markets a portfolio of medical devices and biologic products for the surgical repair of peripheral nerve injuries. Its offerings include the FDA-approved Avance acellular nerve allograft and the Axoguard family of porcine small intestine submucosa (SIS)-based nerve connectors, protectors, and caps, plus the Avive+ Soft Tissue Matrix. Products are sold to hospitals, ambulatory surgical centers, and surgeons for use in extremity, breast reconstruction, and oral maxillofacial/head & neck nerve repair procedures.

Product overview

AxoGen offers a comprehensive suite of surgical products for peripheral nerve repair. The portfolio includes Avance (FDA-approved biologic nerve allograft), the Axoguard family of SIS-based devices (Nerve Connector, Nerve Protector, HA+ Nerve Protector, Nerve Cap), and Avive+ Soft Tissue Matrix. These products address the full spectrum of nerve repair scenarios: Avance provides an acellular nerve scaffold for bridging gaps, the Nerve Connector enables tension-free coaptation for small gaps, the Nerve Protectors wrap and shield injured nerves from soft tissue attachments, the Nerve Cap prevents neuroma formation, and Avive+ provides soft tissue separation. The company transitioned from a medical device platform to a regulated biologics business following FDA approval of Avance in December 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • Avance: FDA-approved acellular nerve allograft for peripheral nerve discontinuities
  • Axoguard
  • Avive+
  • Resensation

Products and services

  • Avance Acellular Nerve Allograft FDA-approved acellular nerve allograft serving as a biologic scaffold for nerve regrowth across peripheral nerve discontinuities in patients aged one month and older. Indicated for surgical nerve repair procedures performed by peripheral nerve, trauma, breast reconstruction, and oral maxillofacial surgeons.
  • Axoguard Nerve Connector Porcine small intestine submucosa (SIS) matrix designed for Connector Assisted Repair of transected nerves with gaps up to 5mm, alleviating tension at the repair site and aiding nerve end alignment for peripheral nerve surgeons.
  • Axoguard Nerve Protector Porcine small intestine submucosa (SIS) implant with a pre-curled design for circumferential wrapping of injured or compressed nerves, minimizing soft tissue attachments during healing for use by peripheral nerve and reconstructive surgeons.
  • Axoguard HA+ Nerve Protector SIS-based nerve protector with a short-term resorbable hyaluronate-alginate gel coating designed to enhance nerve gliding and minimize soft tissue attachments during the critical healing phase for peripheral nerve and reconstructive surgeons.
  • Axoguard Nerve Cap Porcine small intestine submucosa (SIS) matrix with proprietary bifurcation design intended to reduce the development of symptomatic or painful neuromas by minimizing pathological axon interaction, for use in neuroma prevention procedures.
  • Avive+ Soft Tissue Matrix Multi-layer amnion intended for use as a soft tissue barrier in acutely inflamed or irritated environments, resorbing over 16 weeks to provide barrier function through the critical healing phase for surgical applications.

Quantifiable outcome

  • 23.5% year-over-year revenue growth in Q3 2025
  • +4 more outcomes

Companies that use AxoGen

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

AxoGen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

AxoGen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA)coreImplementation/ SI/ Consulting PartnerAxoGen provides experienced coding assistance and Coverage Access Services through MCRA as consulting partner. MCRA staff provides guidance on CPT and ICD-10 codes, claim submission, benefits verification, pre-authorization assistance, and payer-specific pre-determination requests.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

AxoGen competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Stryker is a diversified medical device incumbent with surgical, orthopedic, and neurotechnology portfolios that overlap with Axogen's extremity and reconstructive surgical call points. As a large incumbent, Stryker has the scale and R&D resources to enter the nerve repair space.
  • Medtronic: Medtronic has a strong neurosurgery and ENT portfolio and active peripheral nerve stimulation offerings (e.g., Intellis, Vanta). It serves overlapping surgical specialists and could expand into nerve repair biologics from a position of strength.
  • Cook Medical: Cook Medical sells a broad range of surgical implants and biologic devices (including the Biodesign SIS-based surgical products) that overlap with Axogen's porcine SIS-based Axoguard line in soft tissue and reconstructive surgery.
  • Coloplast: Coloplast is a broad wound and skin care incumbent with Biatain and other advanced wound care products. While not a nerve repair specialist, it competes for surgical wound healing budgets and shares reimbursement-driven hospital channels with Axogen.
  • ConvaTec: ConvaTec is a global wound and skin care company with advanced wound biologics (e.g., InnovaMatrix) that overlap with Axogen's Avive+ soft tissue matrix and compete for the same surgical reimbursement codes.
  • Smith+Nephew: Smith+Nephew is a diversified incumbent with strong surgical and regenerative medicine franchises (including acquired Osiris cartilage and skin products) that overlap with Axogen's regenerative nerve and soft tissue repair products.

Emerging players

  • Organogenesis: Organogenesis is a regenerative medicine company with leading skin substitute products (Apligraf, Dermagraft) targeting wound care and surgical applications adjacent to Axogen's nerve repair and Avive+ matrix portfolio.
  • Vericel: Vericel is a regenerative medicine specialist (MACI, Epicel) targeting surgical and sports medicine indications. While focused on cartilage and burns, it uses a similar hospital-based specialty sales model and biologic reimbursement strategy to Axogen.

Direct peers

  • MiMedx: MiMedx markets EpiFix and AmnioFix amniotic membrane allografts that directly overlap with Axogen's Avive+ Soft Tissue Matrix in surgical and wound applications. Both compete in regenerative soft tissue and use similar direct-to-surgeon field sales models.
  • Integra LifeSciences: Integra is the most direct competitor in peripheral nerve repair, selling NeuraGen nerve guides and NeuraWrap/NeuraWrap+ protectors for nerve coaptation. Both companies target the same hand, plastic, and trauma surgeons with surgical nerve repair solutions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

AxoGen social profiles

Digital presence

AxoGen compliance and trust

Trust signal

Compliance5 records

AxoGen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AxoGen leadership team

Management profile

Number of profiles

Profiles12 records

AxoGen subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

AxoGen funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AxoGen M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AxoGen

What does AxoGen do?

AxoGen develops, manufactures, and markets a portfolio of medical devices and biologic products for the surgical repair of peripheral nerve injuries. Its offerings include the FDA-approved Avance acellular nerve allograft and the Axoguard family of porcine small intestine submucosa (SIS)-based nerve connectors, protectors, and caps, plus the Avive+ Soft Tissue Matrix. Products are sold to hospitals, ambulatory surgical centers, and surgeons for use in extremity, breast reconstruction, and oral maxillofacial/head & neck nerve repair procedures.

Is AxoGen a public or private company?

AxoGen is a public company. It is classified as public and is currently operating.

When was AxoGen founded?

AxoGen was founded in 2002. It employs 501 to 1,000 people.

Where is AxoGen based?

AxoGen is headquartered in Alachua, United States, in the North America region.

How does AxoGen make money?

One revenue line is on record: medical Device and Biologic Product Sales.

Who are AxoGen's main competitors?

Broad incumbents on record are Stryker, Medtronic, Cook Medical, Coloplast, ConvaTec and Smith+Nephew. Emerging players are Organogenesis and Vericel. Direct peers are MiMedx and Integra LifeSciences.

Does AxoGen have an API?

No public API is recorded for AxoGen.

What industry is AxoGen in?

AxoGen's product category is Surgical Nerve Repair Products. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 339112 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAxoGen: 3 Key Takeaways for Long-Term InvestorsAxoGen raised its full-year 2026 revenue guidance to at least $290 million in its Q3 2026 earnings call. The company cited three growth drivers: the NerveTape acquisition, 96% commercial payer coverage for Avance, and prostate nerve reconstruction market development. Revenue grew 26.2% year over year in Q3.The Motley FoolAxoGen: 3 Key Takeaways for Long-Term InvestorsAxoGen raised its full-year 2026 revenue guidance to at least $290 million in its Q3 2026 earnings call. The company highlighted nerve repair portfolio adoption, 96% commercial payer coverage for Avance, and a 2027 prostate nerve reconstruction launch. Revenue grew 26.2% year over year in Q3.Simply Wall StEarnings Upgrades Could Be A Big Deal For Axogen Stock (AXGN)Axogen presented at Canaccord's MedTech forum, reiterating progress on payer access and BioCircuit integration. The company paid $200 million for NerveTape, which has about $24 million in annualized revenue and an 80% gross margin, expected to support adjusted EBITDA margin from 2027. Revenue is projected to grow 24.3% annually to $512.7 million by 2029, implying an earnings swing of about $63.9 million.YahooAxoGen (AXGN) is a Great Momentum Stock: Should You Buy?AxoGen (AXGN) holds a Zacks Momentum Style Score of B and a Zacks Rank of #2 (Buy). Its shares have risen 143.38% over the past year, outperforming the S&P 500's 12.43% gain. The article suggests the stock is a solid momentum pick.American Banking and Market NewsAxoGen, Inc. (NASDAQ:AXGN) Stock Now Rated “Moderate Buy” by Sell-Side AnalystsAxoGen shares received a consensus 'Moderate Buy' rating from 16 analysts, with an average 12-month price target of $57.92. The company reported Q3 EPS of $0.21, beating estimates of $0.13, and revenue of $75.83 million. Analysts predict a loss of $0.36 per share for the current year.Quiver QuantitativeAxogen jumps as investors continue to digest stronger outlook and new prostate program opportunity | AXGN Stock NewsAxogen stock rose 15.2% after the company beat late-October earnings and raised its 2026 outlook. Management also highlighted a new prostate nerve reconstruction opportunity, which may have driven additional investor interest. No separate major press release was issued on the same day.Investing.comAxoGen at Canaccord forum: growth plan widens beyond nerve repairAxoGen outlined a growth plan at a Canaccord forum, citing improved reimbursement and new indications. The company said 90% of commercial lives are covered for nerve work, targeting 100%, and is piloting prostate cancer reconstruction in 10 territories in 2027. It also integrated BioCircuit's NerveTape for nerve repair.Quiver QuantitativeFund Update: 871,949 AXOGEN (AXGN) shares added to Stephens Investment Management Group LLC portfolio | AXGN Stock NewsStephens Investment Management Group LLC added 871,949 shares of AXOGEN to its portfolio, per a new SEC 13F filing for the period ending September 30, 2026. The filing also shows 139 institutional investors added AXOGEN shares while 106 reduced positions in the most recent quarter.American Banking and Market NewsAxoGen, Inc. $AXGN Shares Bought by Calamos Advisors LLCCalamos Advisors increased its AxoGen stake by 15.8% in Q3, holding 110,210 shares valued at $4.62 million. Analysts rate the stock a Moderate Buy with a consensus price target of $57.92. AxoGen reported Q3 EPS of $0.21, beating estimates.American Banking and Market NewsAxoGen (NASDAQ:AXGN) Rating Lowered to Buy at Wall Street ZenWall Street Zen downgraded AxoGen from strong-buy to buy, while other analysts have mixed ratings. The stock opened at $50.02, with a consensus target of $57.92. Insiders sold 84,353 shares over the last 90 days.